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Abstract: 1 
Background: Despite clinical intervention, people with chronic inflammatory 2 
demyelinating polyneuropathy (CIDP) experience difficulties in gait and balance on a 3 
daily basis. However, the effects on these variables of a tailored home based 4 
exercise programme for this population have not been investigated.  This case series 5 
aims to investigate the effects of a home based tailored exercise programme on gait 6 
and balance in people with CIDP. 7 
Methods: Case series of seven people with CIDP from a neurology department of a 8 
local hospital. Participants took part in a 6 week Otago exercise programme, which 9 
include walking, strengthening and balance tasks. Participants were assessed 10 10 
times; 3 times prior, 3 times during an exercise intervention, 3 times post intervention 11 
and once at three months follow up. The outcome measures were Berg Balance 12 
scale, 10 meter walk test, fatigue severity scale and EQ-5D-5L.  13 
Results: Participants showed an increase in walking speed and balance after the 14 
exercise intervention and most kept these improvements at 3 months follow up. 15 
Conclusion: This study shows that exercise can be beneficial for gait and balance in 16 
people with CIDP. These findings are in line with literature from related diseases 17 
such as Guillain-Barre Syndrome. However studies with a larger sample size are 18 
needed to confirm these findings in the population. 19 
  20 
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Introduction 1 
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare and 2 
progressive autoimmune disease of the peripheral nervous system. Yearly up to 3 
approximately 1.6 per 100,000 of the UK population contracts the disease, whereas 4 
8.9/100,000 people are living with CIDP [1].  5 
Characterized by distal and proximal weakness of the upper and lower limbs, the 6 
disease also presents with sensory impairments such as balance disturbance, 7 
numbness of the hands and feet and areflexia [2]. However the presentation of the 8 
symptoms for each individual varies greatly, therefore the population is very 9 
heterogeneous. In addition, motor defects associated with the disorder may lead to 10 
abnormalities in gait, and the long term nature of this condition can lead to 11 
impairment in both psychological and social functioning.  12 
Pharmaceutical approaches have shown the condition responds to treatment with 13 
intravenous-immunoglobulin (IVIG) as the primary treatment preference [3,4], 14 
corticosteroids [5], and plasma exchange (plasmapheresis) [6]. Although these 15 
approaches can reduce the severity of disability in CIDP, administration of these 16 
interventions exposes significant clinical disadvantages such as being expensive, 17 
time-consuming and the development of potentially serious side effects with long 18 
term usage [7]. In addition, maintaining movement and balance throughout the 19 
duration of a treatment cycle may be challenging as the patient’s condition may 20 
deteriorate over time. Despite the use of the medical treatments described above, 21 
clinicians see a significant proportion of patients suffering with moderate to severe 22 
disabilities on the longer-term.  23 
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The benefits of an exercise programme have been shown in Acute Inflammatory 1 
Demyelinating Polyneuropathy or Guillain-Barre Syndrome (GBS). Additional 2 
exercise conducted by a mildly affected patient with GBS showed considerable 3 
improvements in ground reaction forces and lower limb kinematics, indicating a 4 
markedly improved functional gait pattern. This improvement was reinforced by 5 
positive subjective feedback [8]. Further research comparing the impact between 6 
low-intensity and high-intensity ambulatory rehabilitation programme found a clinical 7 
improvement which favoured the high-intensity programme in GBS patients [9]. 8 
Additionally, physical therapy interventions applied to case studies in GBS have also 9 
shown marked improvements in muscle performance and functional independence 10 
[10]. In addition, exercise has been shown to improve other polyneuropathies in 11 
clinical measures of balance and postural instability [11]. Although the mechanisms 12 
that apply to the disease progression between CIDP and GBS are different, scope 13 
for physical improvement in recovery with GBS could still suggest a similar output if 14 
these practices were applied to CIDP patients. 15 
There has been little research over the years providing information on the functional 16 
impact of exercise in CIDP, this is partly due to the rarity of the condition. The 17 
majority of the research has focused on the beneficial effects of exercise within 18 
lifestyle domains, such as improvement in quality of life [12] and activity limitation 19 
[13]. Additionally research has focussed on broader measures of health including 20 
fatigue and mental states such as anxiety and depression in people with CIDP [14]. 21 
Whilst these are important factors in CIDP, as they can significantly disrupt an 22 
individual’s activity within daily living, there is a lack of information on the effect of 23 
physiotherapy interventions and their potential benefit on the physical aspects of 24 
mobility and disability. There is small amount of limited evidence that suggests that 25 
5 
 
focusing on increasing general fitness in this patient group is sufficient for 1 
rehabilitation. However, a case series in patients with CIDP found no relationship 2 
between physical fitness and the patient’s actual mobility using a 12 week training 3 
programme with a singular focus on aerobic training [15]. This could suggest that 4 
patient’s with CIDP may need an exercise programme which is more tailored to 5 
specific patient’s needs. Exercises will most likely vary between patients due to the 6 
heterogeneous presentation of symptoms, with more focus on concentric and 7 
eccentric exercises with an intention to target problematic or weakened muscle 8 
groups to regain strength and balance. 9 
Due to the nature in which the disorder presents itself, the variability of symptoms in 10 
this patient group is quite broad, making it considerably difficult to categorise CIDP 11 
patients as a group. A recent case report investigated a rehabilitation programme 12 
which targeted therapeutic exercise, balance training, and function training with 13 
progressive endurance activities in CIDP [16]. The Functional Independence 14 
Measure was used as a clinical outcome measure; commonly used to measure 15 
disablement and level of independence in patients. The patient with CIDP had an 16 
increase in functional independence, along with improvements in muscle strength 17 
and endurance post-intervention. To build on this evidence a larger group of patients 18 
with CIDP needs to be investigated. Therefore, this clinical case series aims to 19 
investigate the effects of a home based 6 week tailored exercise programme on gait 20 
and balance patients with CIDP.  21 
 22 
Methods 23 
Ethics  24 
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This study was approved by the University Ethics Committee {number} and the 1 
National Research Ethics Service committee {number} 2 
Participant recruitment 3 
A total of 7 participants over the age of 18 with a diagnosis of CIDP or other acquired 4 
inflammatory polyneuropathy and who were on a stable IVIG cycle, between 1-8 5 
weeks consistently for 3 months or more prior to the study, were recruited into the 6 
study. Participants previously received treatment as patients at the local hospital, 7 
and had been diagnosed by a consultant neurologist using clinical assessment and 8 
standard neurophysiological tests.  9 
Exclusion criteria included; no detectable leg weakness, inadequate vision or hearing 10 
to receive instructions, diagnosis of multifocal motor neuropathy, any significant 11 
relevant comorbidity e.g. significant arthritis, cardiac failure, cervical myelopathy 12 
which might affect gait, the need to use  ambulatory aids during walking and any 13 
inconsistent IVIG use throughout the study.  14 
Each participant was presented with information about the study and their right to 15 
withdraw, and gave their full consent to participate by completing a signed consent 16 
form. An Overall Neuropathies Limitation Scale (ONLS) assessment was carried out 17 
prior to the first assessment. The ONLS score was calculated by adding the arm 18 
score to the leg score and ranged from 0 (no disability) to 12 (maximum disability).  19 
Protocol 20 
This clinical case series was based on an AAABBBAAAA design; participants were 21 
assessed three times prior to, three times during, three times post intervention and 22 
once at three months post intervention. The assessment schedule was matched to 23 
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each individual’s IVIG treatment cycle, on average this meant that the first post 1 
intervention assessment was measured three weeks after the intervention was 2 
completed. At each of the 10 assessments four outcome measures were 3 
administered; Berg Balance scale, 10 meter walk test (10MWT), Fatigue Severity 4 
Scale (FSS), and the EQ5D-5L. Six assessments took place at a clinical 5 
rehabilitation unit and four were carried out in a movement laboratory where 6 
additional gait analysis took place. The four laboratory assessments were conducted 7 
during each of the assessment periods; pre-intervention, during the intervention, 8 
post-intervention and at the 3 month follow up. (Figure 1) 9 
Berg Balance scale 10 
The Berg Balance scale [17,18] is a clinical instrument designed to measure balance 11 
performance. Used as an outcome measure, the Berg Balance scale compromises 12 
of a range of 14 balance tasks (e.g. standing on one leg, tandem stepping). 13 
Participants were instructed to perform each of the balance tasks in a standardised 14 
order. Berg Balance results were recorded on a 5-point ordinal scale, ranging from 0-15 
4, with a maximum possible score of 56. Lower scores were associated with more 16 
limited balance in participants. In each assessment the Berg Balance scale was 17 
carried out once. 18 
10 Meter walk test 19 
Participants undertook three 10 MWT during each of the 10 assessments. 20 
Participants were instructed to walk the length of a 10 meter walk way at their own 21 
comfortable speed. Three consecutive 10 MWT were carried out per assessment, 22 
with the middle 6 meters marked out and timed. The average time score was then 23 
taken from the three walks.  24 
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FSS and EQ-5D-5L 1 
The FSS [19] and the EQ-5D-5L health questionnaire [20] were completed based on 2 
how the participants felt that week. The FSS compromises of 9-item questionnaire 3 
relating to fatigue severity on daily living activities. Each question is scored from a 4 
range of 0 (strongly disagree) to 7 (strongly agree), with a maximum score of 63 as a 5 
whole. Additionally participants rated their global fatigue on a visual analogue scale 6 
(VAS).  7 
 8 
The EQ-5D-5L presents a range of 5 sub sections which include Mobility, Self-care, 9 
Usual activities, Pain/Discomfort and Anxiety/Depression. Patients were asked to tick 10 
which box applied to them (e.g. I have no problems/slight problems/moderate 11 
problems/severe problems or unable) within each specific section. The patient’s 12 
perceived general health (EQ-5D-5L) was rated from 0 (being the worst) to 100 13 
(being the best they have felt). 14 
Data analysis 15 
Individual 10MWT scores were compared with Minimal Clinically Important 16 
Differences (MCID) scores obtained from the literature. The MCID was set to 17 
0.05m/s for a small meaningful change and 0.13 m/s for a substantial meaningful 18 
change [21]. Conradsson et al 2007 identified that a change of 7.7 points on the Berg 19 
Balance scale marked a genuine change in function for a participant [22] and this cut 20 
off point was used in this study.  21 
For the complete patient group average scores were taken from the 3 assessments 22 
in the pre-intervention assessment phases and the 3 assessments in the post-23 
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intervention phases for each of the clinical outcome measures. A 10% increase was 1 
set as a meaningful difference between pre- and post-intervention. Paired t-tests 2 
between pre and post intervention scores were then conducted for each outcome 3 
measure (10MWT, Berg Balance, FSS and EQ-5D-5L)  4 
Intervention  5 
The Otago Home Exercise programme [23] was used as the intervention in this 6 
study. Primarily developed to prevent falls, the programme incorporates lower limb 7 
strengthening exercises with dynamic balance retraining exercises. The programme 8 
targets major lower leg muscles and core muscles fundamental for walking and 9 
functional movement and essential for maintaining and recovery of balance. 10 
Activities include sit to stand, walking backwards, walking in a figure of eight and 11 
standing on the toes. During the intervention period, patients were prescribed 12 
personalised exercise plans three times per week with at least two 30 minute walks 13 
per week as instructed from the Otago exercise programme for a total of 6 weeks 14 
(Figure 1). A physiotherapist explained and demonstrated the exercises face to face 15 
at the start of the intervention, after which the participants completed the exercises at 16 
home independently. The participants recorded the amount of completed exercises 17 
on a sheet and the physiotherapist phoned the participants fortnightly to enquire 18 
about their wellbeing and to guide them through their progress. 19 
    Insert Figure 1 here 20 
 21 
Results 22 
Demographics 23 
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Seven participants (5 females, 2 males), participated in this study. One participant 1 
withdrew from the study during the pre-intervention phase for personal reasons. 2 
Therefore results are presented of the six remaining participants. One of these six 3 
participants was unable to complete the 3 month post-assessment follow up, due to 4 
unrelated health issues. Participants were between the ages 48 and 77 years old, 5 
and scored 3 to 5 on the ONLS score. None of the participants changed their IVIG 6 
treatment during the study. 7 
Individual results 8 
Despite a varied response in walking speed and balance during the intervention, 9 
participants presented an overall trend towards an increase in walking speed as a 10 
result of the exercise programme (Table 1, Figure 2). One of the participants 11 
(participant 1) commented that her walking distance improved so greatly that she 12 
was able to walk outside for leisure again. The majority of scores still displayed 13 
either a small or substantial meaningful change in speed at 3 month follow up, with 14 
the exception of participant 7 who showed no change in walking speed across the 15 
assessments.  16 
17 
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Insert Table 1 here 1 
 2 
    Insert Figure 2 here 3 
All participants displayed an increase in balance in scores post-exercise, with the 4 
exception of participant 2 who hit the ceiling of the Berg balance score (56) during 5 
intervention and maintained this maximum score for the duration of the study (Figure 6 
3). This latter participant also commented that she was able to pick up her favourite 7 
sport and therefore improve her participation level. The majority of participants 8 
continued to improve in their balance scores 3 months post intervention. Here it must 9 
be noted that all of the participants continued all or part of their exercises after the 10 
intervention was completed.   11 
Group results 12 
As a patient group, both of the clinical outcomes for the 10 MWT and the Berg 13 
Balance test presented a statistically significant improvement in scores, displaying a 14 
10% improvement in outcome post intervention in comparison to pre-intervention. A 15 
10% improvement in scores were also seen in the secondary outcome measures 16 
FSS and the EQ-5D-5L, however these changes were not statistically significant 17 
(Table 2).  18 
    Insert Table 2 here   19 
 20 
Discussion 21 
 22 
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This study showed that a six week tailored exercise intervention can have a positive 1 
effect on walking speed and balance in people with stable CIDP. This effect was 2 
apparent immediately after the intervention and 3 months after the exercises were 3 
completed. IVIG treatment did not change for any of the participants in this time 4 
period. These results resonate with findings of others who also showed improvement 5 
in functional independence [10] and balance [11] in people with related diseases.  6 
During the intervention a varied response was seen regarding walking speeds and 7 
balance. This variation might be explained by the challenging nature of the balance 8 
and walking exercises, with which some participants initially struggled. This is the 9 
first time that the Otago Exercise programme has been used in this population. In 10 
light of the success of this study it can be concluded that this programme is suitable 11 
for people with CIDP. However a larger study would be needed to determine to what 12 
extent this programme could be effective.  13 
Despite the varied response of the exercise intervention it appeared that the 14 
participants who walked slower also scored lower in the Berg Balance scale. In other 15 
populations, such as people with Parkinson, spinal cord injury and stroke, a 16 
correlation has been shown between walking speed and balance [24-26]. However, it 17 
also showed that participants who walked slower (Participants 4,5,7) also improved 18 
more on the Berg Balance Scale post intervention and continued to improve at 3 19 
months follow up than people who walked faster prior to the intervention. This might 20 
be an effect of the exercise intervention, however it could also be explained by the 21 
masking of the additional gains of the faster walking participants as they were near 22 
the upper limit of the Berg Balance scale. As mentioned in the results one of the 23 
participants reached the ceiling of the Berg Balance scale early in the intervention, 24 
but continued to improve throughout and after the intervention measured by verbal 25 
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feedback. Therefore even though the use of this scale is accepted in CIDP, it did not 1 
capture the limitations of the participants as full marks did not mean that the 2 
participant did not experience any issues [27].  3 
 4 
In line with Graham et al [14] our participants also reported to be less fatigued, 5 
although this was not significant. A study encompassing more participants and 6 
perhaps a longer or more intense intervention could show a significant result. The 7 
reduced fatigue levels in this study could be caused by increased strength levels due 8 
to the intervention, but could also be explained by the possibility that participants 9 
were less depressed due to improved Quality of Life, became less depressed, 10 
became less anxious of the assessments over time or by the day to day variability 11 
seen in this disease [14]. Although the latter is possible this study used an average 12 
of three assessments and assessed the participants at set time points to limit this 13 
effect.  14 
Study limitations 15 
The MCID values used in this study were taken from the literature for older people 16 
[21,22]. Despite of some similarity between this group and the CIDP participants, 17 
there are great differences between them as well. Therefore the effects of the 18 
intervention observed in this study would be more realistic if specific MCID values for 19 
the 10MWT and the Berg Balance scale for people with polyneuropathies existed.   20 
Although case studies are suitable methodological approaches for such a rare and 21 
variable disorder, a larger sample size would be needed to consider an overall 22 
generalization of an exercise program in this patient group. This may explain why we 23 
have seen the beneficial effects in tailored exercise programmes within individual 24 
14 
 
case studies, but there is a lack of evidence to promote exercise as useful for 1 
recovery in CIDP as a whole group. 2 
 3 
Conclusion 4 
Tailored exercises can have a positive effect on walking speed and balance in 5 
people with CIPD. However, further research on a bigger study population is needed 6 
to identify which aspects facilitate this change. 7 
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Table 1: average results of 10MWT, Berg Balance, FSS and EQ-5D-5L index for each participant  1 
Participant Pre During Post  3 Month FU 
1 
  
  
  
10MWT (m/s) 1.18 1.20 1.27* 1.33** 
Berg Balance 53.0 51.7 54.0 53.0 
FSS 42.7 39.0 42.0 42.0 
EQ-5D (index) 0.67 0.65 0.65 0.65 
2 
  
  
  
10MWT (m/s) 1.13 1.26** 1.31** 1.26** 
Berg Balance 47.0 55.7*** 55.7*** 56.0*** 
FSS 32.7 17.7 12.3 11.0 
EQ-5D (index) 0.80 0.84 0.89 0.84 
4 
  
  
  
10MWT (m/s) 0.82 0.81 0.86 0.87* 
Berg Balance 29.3 31.3 32.7 35.0 
FSS 55.7 53.0 55.0 61.0 
EQ-5D (index) 0.62 0.63 0.61 0.63 
5 
  
  
  
10MWT (m/s) 0.46 0.55* 0.59** 0.59** 
Berg Balance 21.0 21.0 22.5 29.0*** 
FSS 50.7 49.3 50.5 50.0 
EQ-5D (index) 0.47 0.45 0.45 0.38 
6 
  
  
  
10MWT (m/s) 0.99 0.96 1.07*  n/a 
Berg Balance 49.0 50.0 53.7  n/a 
FSS 43.0 37.0 43.3  n/a 
EQ-5D (index) 0.63 0.66 0.57 n/a 
7 
  
  
  
10MWT (m/s) 0.80 0.77 0.84 0.78 
Berg Balance 45.7 45.7 51.0 52.0 
FSS 47.7 51.0 41.5 44.0 
EQ-5D (index) 0.44 0.54 0.56 0.65 
* indicates a small meaningful clinical change in walking speed compared to the pre-2 
condition, ** indicates a substantial meaningful clinical change in walking speed compared 3 
to the pre-condition. *** indicates a genuine change in the Berg Balance test for a participant 4 
compared to the pre-condition. No meaningful clinical differences were set a priori for the 5 
FSS and EQ-5D.  6 
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Table 2: Differences and percentage change of 10MWT, Berg Balance, FSS and EQ-5D5L-1 
VAS for the 6 participants combined 2 
Outcome measure 
 
p values Percentage change  
10MWT (m/s) 0.007* 10.4% 
Berg Balance 0.016* 10.0% 
FSS 0.220 -10.2% 
EQ-5D VAS 0.323 12.2% 
Results of paired t-test as a patient group for each clinical outcome measure pre vs post – 3 
intervention, *p-value <0.05  4 
  5 
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 1 
2 
Figure 1: Overview of the 10 participant assessments and exercise intervention throughout 3 
the study  4 
A: Pre B: During A:Post
A:3 months 
follow up
6 week 
intervention 
3 x exercise/week 
2 x walking/week 
Lab assessment Hospital assessment 
10 4 5 6 1 2 3 7 8 9 
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 1 
Figure 2: 10 meter walk values with standard deviation bars for each participant.  The pre 2 
(1), during (2), and post (3) values each represent the average of  three assessments. The 3 3 
month value (4) represents one assessment. Participant 6 was not able to complete the follow 4 
up assessment at 3 months. 5 
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 1 
Figure 3: Berg Balance values with standard deviation bars for each participant. The pre (1), 2 
during (2), and post (3) values each represent the average of  three assessments. The 3 month 3 
value (4) represents one assessment. Participant 6 was not able to complete the follow up 4 
assessment at 3 months.   5 
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